TASLY(SH:600535) Ge Long Hui·2025-09-22 08:21Core Viewpoint - Tianjin Tasly Pharmaceutical has received approval from the National Medical Products Administration for its product, recombinant human urokinase (Puyouke), to be used for thrombolytic treatment of acute ischemic stroke, expanding its product line in the neurology/psychiatry sector [1] Group 1 - The company’s wholly-owned subsidiary, Tasly Biopharmaceuticals, has been granted a drug registration certificate for Puyouke, which is the only approved recombinant human urokinase product in China [1] - Puyouke was previously approved for the treatment of acute ST-segment elevation myocardial infarction, and the new indication for acute ischemic stroke enhances the company's offerings in the neurological field [1] - This product is recognized as a Class 1 innovative biological drug supported by the "Major New Drug Creation" project during the "11th Five-Year Plan" period [1]